Freeline Therapeutics Holdings PLC reports results for the quarter ended in September - Earnings Summary

Freeline Therapeutics Holdings

16/11/2022 22:32

* Freeline Therapeutics Holdings PLC  FRLN.OQ  reported a
quarterly adjusted loss of 20 cents​​ per share for the quarter
ended in September. The mean expectation of six analysts for the
quarter was for a loss of 44 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Freeline Therapeutics Holdings PLC's reported EPS for the
quarter was a loss of 20 cents​.
    * The mean earnings estimate of analysts had risen by
about 9.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Freeline Therapeutics Holdings PLC shares had fallen
by 2.9%
this quarter and lost 65.7% so far this year.
    * The company reported a quarterly loss of $14.89 million.
    * Wall Street's median 12-month price target for Freeline
Therapeutics Holdings PLC is $2.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
16 at 10:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.44          -0.20          Beat
 Jun. 30 2022      -0.51          -0.32          Beat
 Mar. 31 2022      -0.60          -0.63          Missed
 Dec. 31 2021      -0.68          -0.96          Missed